Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Database
Language
Publication year range
1.
J Lipid Res ; 58(6): 1166-1173, 2017 06.
Article in English | MEDLINE | ID: mdl-28413163

ABSTRACT

Angiopoietin-like (ANGPTL)3 and ANGPTL8 are secreted proteins and inhibitors of LPL-mediated plasma triglyceride (TG) clearance. It is unclear how these two ANGPTL proteins interact to regulate LPL activity. ANGPTL3 inhibits LPL activity and increases serum TG independent of ANGPTL8. These effects are reversed with an ANGPTL3 blocking antibody. Here, we show that ANGPTL8, although it possesses a functional inhibitory motif, is inactive by itself and requires ANGPTL3 expression to inhibit LPL and increase plasma TG. Using a mutated form of ANGPTL3 that lacks LPL inhibitory activity, we demonstrate that ANGPTL3 activity is not required for its ability to activate ANGPTL8. Moreover, coexpression of ANGPTL3 and ANGPTL8 leads to a far more efficacious increase in TG in mice than ANGPTL3 alone, suggesting the major inhibitory activity of this complex derives from ANGPTL8. An antibody to the C terminus of ANGPTL8 reversed LPL inhibition by ANGPTL8 in the presence of ANGPTL3. The antibody did not disrupt the ANGPTL8:ANGPTL3 complex, but came in close proximity to the LPL inhibitory motif in the N terminus of ANGPTL8. Collectively, these data show that ANGPTL8 has a functional LPL inhibitory motif, but only inhibits LPL and increases plasma TG levels in mice in the presence of ANGPTL3.


Subject(s)
Angiopoietin-like Proteins/metabolism , Lipoprotein Lipase/antagonists & inhibitors , Peptide Hormones/metabolism , Triglycerides/blood , Amino Acid Motifs , Amino Acid Sequence , Angiopoietin-Like Protein 3 , Angiopoietin-Like Protein 8 , Angiopoietin-like Proteins/chemistry , Angiopoietin-like Proteins/deficiency , Animals , CHO Cells , Cricetinae , Cricetulus , HEK293 Cells , Humans , Hypertriglyceridemia/metabolism , Lipoprotein Lipase/metabolism , Mice , Peptide Hormones/chemistry , Peptide Hormones/deficiency
2.
Circ Cardiovasc Genet ; 8(2): 343-50, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25632026

ABSTRACT

BACKGROUND: Exome sequencing is a promising tool for gene mapping in Mendelian disorders. We used this technique in an attempt to identify novel genes underlying monogenic dyslipidemias. METHODS AND RESULTS: We performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gene sequencing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-density lipoprotein cholesterol. We used standard analytic approaches to identify candidate variants and also assigned a polygenic score to each individual to account for their burden of common genetic variants known to influence lipid levels. In 9 families, we identified likely pathogenic variants in known lipid genes (ABCA1, APOB, APOE, LDLR, LIPA, and PCSK9); however, we were unable to identify obvious genetic etiologies in the remaining 32 families, despite follow-up analyses. We identified 3 factors that limited novel gene discovery: (1) imperfect sequencing coverage across the exome hid potentially causal variants; (2) large numbers of shared rare alleles within families obfuscated causal variant identification; and (3) individuals from 15% of families carried a significant burden of common lipid-related alleles, suggesting complex inheritance can masquerade as monogenic disease. CONCLUSIONS: We identified the genetic basis of disease in 9 of 41 families; however, none of these represented novel gene discoveries. Our results highlight the promise and limitations of exome sequencing as a discovery technique in suspected monogenic dyslipidemias. Considering the confounders identified may inform the design of future exome sequencing studies.


Subject(s)
Dyslipidemias/genetics , Exome , High-Throughput Nucleotide Sequencing , Metabolism, Inborn Errors/genetics , Female , Humans , Male
3.
J Lipid Res ; 55(3): 493-503, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24293640

ABSTRACT

ABCA12 mutations disrupt the skin barrier and cause harlequin ichthyosis. We previously showed Abca12(-/-) skin has increased glucosylceramide (GlcCer) and correspondingly lower amounts of ceramide (Cer). To examine why loss of ABCA12 leads to accumulation of GlcCer, de novo sphingolipid synthesis was assayed using [(14)C]serine labeling in ex vivo skin cultures. A defect was found in ß-glucocerebrosidase (GCase) processing of newly synthesized GlcCer species. This was not due to a decline in GCase function. Abca12(-/-) epidermis had 5-fold more GCase protein (n = 4, P < 0.01), and a 5-fold increase in GCase activity (n = 3, P < 0.05). As with Abca12(+/+) epidermis, immunostaining in null skin showed a typical interstitial distribution of the GCase protein in the Abca12(-/-) stratum corneum. Hence, we tested whether the block in GlcCer conversion could be circumvented by topically providing GlcCer. This approach restored up to 15% of the lost Cer products of GCase activity in the Abca12(-/-) epidermis. However, this level of barrier ceramide replacement did not significantly reduce trans-epidermal water loss function. Our results indicate loss of ABCA12 function results in a failure of precursor GlcCer substrate to productively interact with an intact GCase enzyme, and they support a model of ABCA12 function that is critical for transporting GlcCer into lamellar bodies.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Epidermis/metabolism , Glucosylceramidase/metabolism , Glucosylceramides/metabolism , ATP-Binding Cassette Transporters/deficiency , ATP-Binding Cassette Transporters/genetics , Animals , Ceramides/analysis , Ceramides/metabolism , Chromatography, Thin Layer , Epidermis/drug effects , Epidermis/embryology , Glucosylceramides/administration & dosage , Glucosylceramides/pharmacology , HEK293 Cells , Humans , Immunoblotting , Immunohistochemistry , Lipids/analysis , Lipids/chemistry , Mice , Mice, Knockout , Organ Culture Techniques , Reverse Transcriptase Polymerase Chain Reaction , Skin/drug effects , Skin/embryology , Skin/metabolism
4.
PLoS One ; 7(4): e34904, 2012.
Article in English | MEDLINE | ID: mdl-22493722

ABSTRACT

In obesity, there is an increase in reactive oxygen species (ROS) within adipose tissue caused by increases in inflammation and overnutrition. Hormone sensitive lipase (HSL) is part of the canonical lipolytic pathway and critical for complete lipolysis. This study hypothesizes that ROS is a signal that integrates regulation of lipolysis by targeting HSL. Experiments were performed with human differentiated adipocytes from the subcutaneous depot. Antioxidants were employed as a tool to decrease ROS, and it was found that scavenging ROS with diphenyliodonium, N-acetyl cysteine, or resveratrol decreased lipolysis in adipocytes. HSL phosphorylation of a key serine residue, Ser552, as well as translocation of this enzyme from the cytosol to the lipid droplet upon lipolytic stimulation were both abrogated by scavenging ROS. The phosphorylation status of other serine residues on HSL were not affected. These findings are significant because they document that ROS contributes to the physiological regulation of lipolysis via an effect on translocation. Such regulation could be useful in developing new obesity therapies.


Subject(s)
Adipocytes/drug effects , Adipose Tissue/drug effects , Reactive Oxygen Species/metabolism , Signal Transduction , Sterol Esterase/metabolism , Acetylcysteine/pharmacology , Adipocytes/metabolism , Adipocytes/pathology , Adipose Tissue/metabolism , Adipose Tissue/pathology , Adult , Antioxidants/pharmacology , Biphenyl Compounds/pharmacology , Colforsin/adverse effects , Female , Humans , Lipids/chemistry , Lipolysis/drug effects , Middle Aged , Obesity/metabolism , Obesity/pathology , Onium Compounds/pharmacology , Phosphorylation/drug effects , Primary Cell Culture , Protein Transport/drug effects , Reactive Oxygen Species/antagonists & inhibitors , Resveratrol , Serine/metabolism , Stilbenes/pharmacology
5.
Biochim Biophys Acta ; 1812(11): 1393-402, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21787864

ABSTRACT

Inherited glucose-6-phosphate isomerase (GPI) deficiency is the second most frequent glycolytic erythroenzymopathy in humans. Patients present with non-spherocytic anemia of variable severity and with neuromuscular dysfunction. We previously described Chinese hamster (CHO) cell lines with mutations in GPI and loss of GPI activity. This resulted in a temperature sensitivity and severe reduction in the synthesis of glycerolipids due to a reduction in phosphatidate phosphatase (PAP). In the current article we attempt to describe the nature of this pleiotropic effect. We cloned and sequenced the CHO lipin 1 cDNA, a gene that codes for PAP activity. Overexpression of lipin 1 in the GPI-deficient cell line, GroD1 resulted in increased PAP activity, however it failed to restore glycerolipid biosynthesis. Fluorescence microscopy showed a failure of GPI-deficient cells to localize lipin 1α to the nucleus. We also found that glucose-6-phosphate levels in GroD1 cells were 10-fold over normal. Lowering glucose levels in the growth medium partially restored glycerolipid biosynthesis and nuclear localization of lipin 1α. Western blot analysis of the elements within the mTOR pathway, which influences lipin 1 activity, was consistent with an abnormal activation of this system. Combined, these data suggest that GPI deficiency results in an accumulation of glucose-6-phosphate, and possibly other glucose-derived metabolites, leading to activation of mTOR and sequestration of lipin 1 to the cytosol, preventing its proper functioning. These results shed light on the mechanism underlying the pathologies associated with inherited GPI deficiency and the variability in the severity of the symptoms observed in these patients.


Subject(s)
Anemia, Hemolytic, Congenital Nonspherocytic/etiology , Cell Nucleus/metabolism , Glucose-6-Phosphate Isomerase/metabolism , Glucose/pharmacology , TOR Serine-Threonine Kinases/metabolism , Amino Acid Sequence , Animals , Blotting, Western , CHO Cells , Cloning, Molecular , Cricetinae , Electrophoretic Mobility Shift Assay , Fructosephosphates/metabolism , Glucose-6-Phosphate/metabolism , Glucose-6-Phosphate Isomerase/genetics , Glycolipids , Microscopy, Fluorescence , Molecular Sequence Data , Organic Chemicals/metabolism , Phosphatidate Phosphatase/metabolism , Protein Transport , Sequence Homology, Amino Acid
6.
J Biol Chem ; 285(2): 866-77, 2010 Jan 08.
Article in English | MEDLINE | ID: mdl-19903819

ABSTRACT

Glycerolipids are structural components for membranes and serve in energy storage. We describe here the use of a photodynamic selection technique to generate a population of Chinese hamster ovary cells that display a global deficiency in glycerolipid biosynthesis. One isolate from this population, GroD1, displayed a profound reduction in the synthesis of phosphatidylcholine, phosphatidylethanolamine, and triglycerides but presented high levels of phosphatidic acid and normal levels of phosphatidylinositol synthesis. This was accompanied by a reduction in phosphatidate phosphatase 1 (PAP1) activity. Expression cloning and sequencing of the cDNA obtained from GroD1 revealed a point mutation, Gly-189 --> Glu, in glucose-6-phosphate isomerase (GPI), a glycolytic enzyme involved in an inherited disorder that results in anemia and neuromuscular symptoms in humans. GPI activity was reduced by 87% in GroD1. No significant differences were found in DNA synthesis, protein synthesis, and ATP levels, whereas glycerol 3-phosphate levels were increased in the mutant. Expression of wild-type hamster GPI restored GPI activity, glycerolipid biosynthesis, and PAP1 activity in GroD1. Two additional, independently isolated GPI-deficient mutants displayed similar phenotypes with respect to PAP1 activity and glycerolipid biosynthesis. These findings uncover a novel relationship between GPI, involved in carbohydrate metabolism, and PAP1, a lipogenic enzyme. These results may also help to explain neuromuscular symptoms associated with inherited GPI deficiency.


Subject(s)
Glucose-6-Phosphate Isomerase/metabolism , Phospholipids/biosynthesis , Triglycerides/biosynthesis , Anemia/enzymology , Anemia/genetics , Animals , Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , CHO Cells , Cricetinae , Cricetulus , Glucose-6-Phosphate Isomerase/genetics , Humans , Lectins, C-Type/genetics , Lectins, C-Type/metabolism , Metabolism, Inborn Errors/enzymology , Metabolism, Inborn Errors/genetics , Neuromuscular Diseases/enzymology , Neuromuscular Diseases/genetics , Pancreatitis-Associated Proteins , Phospholipids/genetics , Point Mutation , Triglycerides/genetics
7.
Int J Biol Macromol ; 31(1-3): 19-27, 2002 Dec 20.
Article in English | MEDLINE | ID: mdl-12559423

ABSTRACT

Acyl-CoA binding protein (ACBP) and fatty acid binding protein (FABP) are intracellular transporters of activated and free fatty acids, respectively. Unlike other tissues with active lipid metabolism, armadillo Harderian gland contains much more ACBP than FABP. To characterize armadillo ACBP structure and binding properties, we produced it in Escherichia coli and carried out detailed fluorescence and circular dichroism spectroscopy studies. The K(D) for palmitoyl-CoA, measured directly by fluorescence and rotatory power, was 34+/-12 and 75+/-39 nM, respectively. The structure of armadillo ACBP appears to be very similar to that of bovine and rat liver ACBPs.


Subject(s)
Diazepam Binding Inhibitor/chemistry , Amino Acid Sequence , Animals , Armadillos , Base Sequence , Cattle , Circular Dichroism , Escherichia coli/metabolism , Kinetics , Liver/enzymology , Molecular Sequence Data , Protein Binding , Proteins/chemistry , Rats , Spectrometry, Fluorescence , Temperature , Thermodynamics , Ultraviolet Rays
SELECTION OF CITATIONS
SEARCH DETAIL